What question did this study set out to answer?

To explore the anti-tumor mechanisms of 212Pb-PSMA radioligand therapy in prostate cancer.

Mechanistic Insights into 212Pb-PSMA Radioligand Therapy for Prostate Cancer

View Full Paper

Ask AI

Bookmark

To explore the anti-tumor mechanisms of 212Pb-PSMA radioligand therapy in prostate cancer.
Utilized 212Pb-ADVC001 for treatment in Phase I/II clinical development
Conducted in vitro and ex vivo studies using transcriptomics and proteomics
Performed functional assays to evaluate effects on cell cycle progression, ROS generation, and lipid peroxidation
212Pb-ADVC001 showed potent cytotoxic activity with EC50 values of 2.7, 7.2, and 3.3 kBq/mL in different PC cell lines
Transcriptomic and proteomic analyses indicated mechanisms involving DNA damage and cell cycle arrest
Functional assays confirmed significant increases in ROS production and lipid peroxidation upon treatment
212Pb-ADVC001 caused notable DNA damage and increased G1- and G2/M-phase arrest compared to 177Lu-PSMA-I&T

No takes yet. Share an insight, caveat, or question.

Investigates the anti-tumor mechanisms of 212Pb-PSMA in prostate cancer, suggesting potential advancements in treatment efficacy.

Liu et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark